BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sun J, Zhou G, Xie X, Gu W, Huang J, Zhu D, Hu W, Hou Q, Shi C, Li T, Zhang X, Ji W, Ying S, Peng Z, Zhou J, Yu Z, Ji J, Du H, Guo X, Fang J, Han J, Xu H, Sun Z, Yu W, Shao G, Wu X, Hu H, Li L, Zheng J, Luo J, Chen Y, Cao G, Hu T. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres® in 275 Hepatocellular Carcinoma Patients: Results From the Chinese CalliSpheres® Transarterial Chemoembolization in Liver Cancer (CTILC) Study. Oncol Res 2020;28:75-94. [PMID: 31558180 DOI: 10.3727/096504019X15662966719585] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Wang CY, Xia JG, Yang ZQ, Zhou WZ, Chen WH, Qi CJ, Gu JP, Wang Q. Transarterial chemoembolization with medium-sized doxorubicin-eluting Callisphere is safe and effective for patients with hepatocellular carcinoma. Sci Rep 2020;10:4434. [PMID: 32157110 DOI: 10.1038/s41598-020-61209-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
2 Liang B, Makamure J, Shu S, Zhang L, Sun T, Zheng C. Treatment Response, Survival, and Safety of Transarterial Chemoembolization With CalliSpheres® Microspheres Versus Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma: A Meta-Analysis. Front Oncol 2021;11:576232. [PMID: 33796448 DOI: 10.3389/fonc.2021.576232] [Reference Citation Analysis]
3 Shao G, Zou Y, Lucatelli P, Tsilimigras DI, Shimise S, Kawaguchi T. Chinese expert consensus on technical recommendations for the standard operation of drug-eluting beads for transvascular embolization. Ann Transl Med 2021;9:714. [PMID: 33987412 DOI: 10.21037/atm-21-1678] [Reference Citation Analysis]
4 Shang B, Li J, Wang X, Li D, Liang B, Wang Y, Han X, Dou W, Chen G, Shang J, Jiang S. Clinical effect of bronchial arterial infusion chemotherapy and CalliSpheres drug-eluting beads in patients with stage II-IV lung cancer: A prospective cohort study. Thorac Cancer 2020;11:2155-62. [PMID: 32603550 DOI: 10.1111/1759-7714.13522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Shi Q, Liu J, Li T, Zhou C, Wang Y, Huang S, Yang C, Chen Y, Xiong B. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: a single-center propensity score matching analysis: DEB-TACE vs cTACE for HCC beyond up-to-seven criteria. Clin Res Hepatol Gastroenterol 2022;:101893. [PMID: 35247625 DOI: 10.1016/j.clinre.2022.101893] [Reference Citation Analysis]
6 Takaya H, Namisaki T, Takeda S, Kaji K, Ogawa H, Ishida K, Tsuji Y, Takagi H, Ozutsumi T, Fujinaga Y, Furukawa M, Kitagawa K, Nishimura N, Sawada Y, Shimozato N, Kawaratani H, Moriya K, Akahane T, Mitoro A, Yoshiji H. The Combination of Albumin-Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child-Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven Criteria. J Clin Med 2021;10:4838. [PMID: 34768358 DOI: 10.3390/jcm10214838] [Reference Citation Analysis]
7 Zhang L, Sun JH, Ji JS, Zhong BY, Zhou GH, Song JJ, Hou ZH, Huang P, Zhang S, Li Z, Zhu XL, Ni CF. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study. AJR Am J Roentgenol 2021;217:933-43. [PMID: 33245680 DOI: 10.2214/AJR.20.24708] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]